This hypothesis is further supported by the results of bivamelagons phase II trial in patients with HO, where bivamelagon was able to achieve BMI reductions comparable to setmelanotide (NCT06046443, NCT07156578) (103, 104)
Timothy Garvey from the University of Alabama says this is a game changer and states we have not seen this degree of weight loss with any previous medication
The biologically active circulating form of GLP-1 is GLP-1 (7-36) amide, a 30-amino-acid peptide generated from post-translational processing of the proglucagon precursor and featuring a naturally occurring C-terminal amidation (-NH) [2]
Its main function is to assist long-chain fatty acids in undergoing beta-oxidation, facilitating the body's utilization of fat, including burning excess fat for energy, without side effects
[DOI] [PMC free article] [PubMed] [Google Scholar] 345.Tilly M.J., Geurts S., Pezzullo A.M., Bramer W.M., de Groot N.M.S., Kavousi M., de Maat M.P.M